MarketFriction

Biofil Chemicals & Pharmaceuticals Ltd

NSE BIOFILCHEM · BSE 524396 · Pharmaceuticals
₹29.31 -3.52%
NSE close2026-10-01
52 week range25.60 - 46.34
Market cap₹51.8 Cr.
P/E108
Price band 20% Delivery 58.7%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales17.375.0315.208.442.4114.208.356.4313.540.867.5712.35
Expenses17.134.8415.248.132.2913.898.246.4213.420.777.1412.21
Operating Profit0.240.19-0.040.310.120.310.110.010.120.090.430.14
OPM %1.38%3.78%-0.26%3.67%4.98%2.18%1.32%0.16%0.89%10.47%5.68%1.13%
Other Income0.030.030.410.030.020.020.242.830.060.080.110.06
Interest0.010.000.020.010.010.010.010.010.000.000.000.00
Depreciation0.110.110.080.100.100.100.080.070.070.070.070.07
Profit before tax0.150.110.270.230.030.220.262.760.110.100.470.13
Tax %20.00%18.18%11.11%26.09%33.33%27.27%23.08%12.68%27.27%30.00%55.32%23.08%
Net Profit0.120.090.250.170.020.160.202.410.080.080.210.11
EPS in Rs0.070.060.150.100.010.100.121.480.050.050.130.07
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales13.1713.4512.3623.1329.6935.7522.3830.0440.0433.4028.4034.32
Expenses12.3010.8411.4322.1127.8734.1521.0528.8839.2332.5527.7533.54
Operating Profit0.872.610.931.021.821.601.331.160.810.850.650.78
OPM %6.61%19.41%7.52%4.41%6.13%4.48%5.94%3.86%2.02%2.54%2.29%2.27%
Other Income0.530.140.100.100.170.800.150.100.490.313.080.31
Interest0.150.160.150.160.120.070.040.040.040.040.010.00
Depreciation0.260.280.300.370.410.410.430.430.400.380.270.28
Profit before tax0.992.310.580.591.461.921.010.790.860.743.450.81
Tax %20.20%22.51%20.69%20.34%17.81%34.90%31.68%29.11%17.44%24.32%19.13%
Net Profit0.781.790.470.481.211.240.700.560.710.562.790.48
EPS in Rs0.481.100.290.290.740.760.430.340.440.341.710.30
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth8%-5%-2%9%
Compounded Profit Growth%%%-83%
Stock Price CAGR15%-13%-13%-25%
Return on Equity5%2%1%-3%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16.2716.2716.2716.2716.2716.2716.2716.2716.2716.2716.2716.27
Reserves-7.86-5.37-3.58-3.11-2.62-1.39-0.140.561.031.932.515.29
Borrowings2.981.371.431.561.641.190.430.460.520.440.473.02
Other Liabilities2.3611.877.729.448.9326.3016.681.4413.5828.4431.7018.26
Total Liabilities13.7524.1421.8424.1624.2242.3733.2418.7331.4047.0850.9542.84
Fixed Assets9.068.989.169.2510.2910.099.789.429.008.628.346.94
CWIP0.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets4.6915.1612.6814.9113.9332.2823.469.3122.4038.4642.6135.90
Total Assets13.7524.1421.8424.1624.2242.3733.2418.7331.4047.0850.9542.84
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0.010.140.710.461.260.891.11-0.22-0.112.39-1.92-0.60
Cash from Investing Activity-0.17-0.19-0.48-0.38-1.41-0.21-0.10-0.07-0.01-0.02-0.101.14
Cash from Financing Activity0.110.10-0.11-0.02-0.08-0.57-0.83-0.010.02-0.120.002.54
Net Cash Flow-0.050.050.130.06-0.240.120.18-0.30-0.112.25-2.033.07
Free Cash Flow-0.16-0.050.230.08-0.150.681.01-0.29-0.122.37-2.020.54
CFO/OP19%33%35%103%134%63%112%8%10%314%-205%9%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days227.35387.45311.00383.31189.84365.25175.81116.94249.08301.10418.77354.59
Inventory Days15.993.467.2938.1121.7324.3748.8524.2016.1124.8139.5256.24
Days Payable198.49400.98304.52341.46156.66373.80178.3911.25168.39268.08366.66239.87
Cash Conversion Cycle44.85-10.0713.7679.9554.9015.8246.27129.8896.8057.8391.63170.96
Working Capital Days-47.9648.5087.65104.8350.8155.6964.12125.25104.2569.37114.09152.17
ROCE %8.59%9.64%18.72%5.06%5.00%10.08%12.20%6.20%4.73%4.94%4.12%2.97%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters46.82%46.82%46.82%46.82%46.82%46.82%46.82%46.82%46.79%46.79%46.79%46.79%
FIIs0.00%0.00%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DIIs0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%
Public53.10%53.11%53.08%53.11%53.10%53.11%53.11%53.10%53.12%53.13%53.12%53.13%
No. of Shareholders26,12325,86426,58125,48026,42226,11425,91425,68525,19624,82525,35624,999

Fundamentals

Market Cap₹ 51.8 Cr.
Current Price₹ 31.8
Stock P/E108
Book Value₹ 13.2
ROCE2.97 %
ROE-2.83 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)-83%
Standalone figures.
Valuation
Market capRs 48 Cr
Enterprise valueRs 47 Cr
P/E (TTM)99.37x
Price to book2.21x
Price to sales1.39x
EV / EBITDA43.08x
EV / EBIT57.79x
EV / sales1.38x
Earnings yield1.01%
P/E, 3-year average91.19x
P/B, 3-year average3.64x
P/E, 5-year average105.58x
P/B, 5-year average4.08x
Profitability
Operating margin (excl. other income)2.29%
Operating margin (incl. other income)13.13%
EBITDA margin3.21%
Pre-tax margin2.36%
Net profit margin1.40%
Net margin, latest quarter0.89%
ROE13.83%
ROCE15.79%
ROA5.95%
ROE, 3-year average6.95%
ROCE, 3-year average8.28%
ROA, 3-year average2.97%
ROE, 5-year average5.68%
ROCE, 5-year average7.15%
ROA, 5-year average2.77%
ROIC (approx.)3.12%
Tax rate19.13%
Other income / net worth14.29%
Growth
Sales growth (latest year)-14.97%
Profit growth (latest year)398.21%
Sales CAGR, 3 years-1.85%
Sales CAGR, 5 years-4.50%
Profit CAGR, 3 years70.79%
Profit CAGR, 5 years17.61%
Sales growth QoQ63.14%
Profit growth QoQ-47.62%
Sales growth YoY (latest quarter)92.07%
Profit growth YoY (latest quarter)-95.44%
Per share
EPS (TTM)Rs 0.29
EPS (latest year)Rs 1.71
EPS (latest quarter)Rs 0.07
EPS, 3-year averageRs 0.83
EPS, 5-year averageRs 0.65
Book value per shareRs 13.25
Sales per shareRs 21.09
Cash flow per shareRs -0.37
Free cash flow per shareRs 0.33
Efficiency
Asset turnover0.66x
Fixed asset turnover4.09x
Inventory turnover6.58x
Inventory days55 days
Debtor days355 days
Debtors turnover1.03x
Creditor days240 days
Cash conversion cycle171 days
Working capital days152 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 3 Cr
Net debtRs -0 Cr
Debt to equity0.14x
Net debt / EBITDA-0.28x
Interest coverage82.00x
Owners' fund to total sources50.33%
Debt to assets7.05%
Cash flow
Cash from Operating Activity (latest year)Rs -1 Cr
Cash from Investing Activity (latest year)Rs 1 Cr
Cash from Financing Activity (latest year)Rs 3 Cr
Net Cash Flow (latest year)Rs 3 Cr
Free cash flow (latest year)Rs 1 Cr
FCFE (approx.: FCF + change in debt)Rs 3 Cr
Cash from ops / profit, 5 years-0.09x
Statement figures
Net sales (TTM)Rs 34 Cr
Net sales (latest year)Rs 28 Cr
Sales (latest quarter)Rs 12 Cr
Operating profit excl. other income (latest year)Rs 1 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 3 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 26 Cr
Total expenditure (latest year)Rs 28 Cr
Total income (latest year)Rs 31 Cr
Share capitalRs 16 Cr
ReservesRs 5 Cr
Shareholders' fundsRs 22 Cr
Total assetsRs 43 Cr
Net blockRs 7 Cr
ReceivablesRs 28 Cr
InventoryRs 4 Cr
Other liabilitiesRs 18 Cr
Shares outstanding (crore)1.63
Ownership
Promoter holding46.79% (-0.03 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 99.4 is at the 58th percentile of its own 9.4-year range (median 80.8, low 12.1, high 294.2).
P/B 2.21 is at the 27th percentile (median 3.95).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodBIOFILCHEMNifty 50Difference
1 week-9.3%-2.8% -6.6 pts
1 month-8.8%-6.8% -2.0 pts
3 months-13.1%-7.6% -5.4 pts
6 months+13.6%+0.4% +13.2 pts
1 year-29.5%-9.9% -19.5 pts
2 years-64.9%-13.6% -51.3 pts
3 years-39.6%+14.2% -53.8 pts
5 years-53.5%+27.9% -81.4 pts

Red flags

F-score 4 of 8
explainWeak cash conversion Cash from operations was -3% of net profit over the last 3 years
lookInventory outrunning sales Inventory grew 20% vs sales -15% in 2026
lookProfit leans on other income Other income was 89% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹12 Cr +92.1% vs Jun 2025. Net profit ₹0 Cr -95.4%.
Against our estimate for Jun 2026: sales +220.1%, profit -52.8% in line. Our estimate for Sep 2026: sales Rs 19 Cr, profit Rs 0 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-09-23Annual General Meeting
2023-09-20Annual General Meeting
2022-09-21Annual General Meeting
2021-09-17 Annual General Meeting
2020-09-21 Annual General Meeting
2019-09-18 Annual General Meeting
2018-09-18 Annual General Meeting
2017-09-14 Annual General Meeting
2016-09-22 Annual General Meeting
2015-09-16 Annual General Meeting
2014-09-18Annual General Meeting
2013-09-19Annual General Meeting
2012-09-20Annual General Meeting
2011-09-22Annual General Meeting
2009-09-23Annual General Meeting
2008-09-19Annual General Meeting
2007-09-20Agm
2006-09-21Agm
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Biofil Chemicals & Pharmaceuticals Ltd?

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) has a market capitalisation of Rs 51.8 Cr. at the 2026-10-01 close.

What is the P/E ratio of Biofil Chemicals & Pharmaceuticals Ltd?

Biofil Chemicals & Pharmaceuticals Ltd trades at a P/E of 108 on trailing twelve-month profit, at the 2026-10-01 close.

What were Biofil Chemicals & Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Biofil Chemicals & Pharmaceuticals Ltd sales was Rs 12 Cr (+92.1% vs Jun 2025) and net profit was Rs 0 Cr.

What is the 52-week high and low of Biofil Chemicals & Pharmaceuticals Ltd?

The 52-week high is Rs 46.34 and the 52-week low is Rs 25.60.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03